Aesica Announces FDA Approvals for Germany Facility

Article

Aesica announced that it received continuing approvals from FDA for its bulk manufacturing and packaging operations in Germany.

 

Aesica, which is a contract development and manufacturing organization, announced on Feb. 2, 2015 that it would continue to grow its manufacturing and packaging services of pharmaceutical products bound for the United States. This announcement comes after the company received FDA pre-approvals for its Germany facilities in Zwickau and Monheim.

The Zwickau site offers bulk manufacture of pharmaceutical tablets, capsules, and controlled release products, with more than 90 products from more than 40 APIs. The Monheim facility houses logistics and distribution centers, with packaging for 1100 SKUs with multiple indications for all geographic markets. In addition to FDA approvals, the sites have also attained successful inspections from ANVISA (for the Brazilian market) and from the German Health Agency.

Source: Aesica

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes